The use of adjunctive antiplatelet and antithrombotic strategies for PCI will be the focus of this case-based session. The role of heparin vs bivalirudin, 2b/3a inhibitors, intravenous antiplatelet agents, and the various P2Y12 inhibitors will be discussed. We will compare clopidogrel, prasugrel, ticagrelor, and cangrelor in real-world practice. The critical issue of duration of dual antiplatelet therapy will be reviewed with emphasis on clinical presentation, lesion complexity, bleeding risk and the stent/drug interface. Finally the specific issue of PCI in patients requiring anticoagulation for atrial fibrillation will be addressed.
After viewing this session, attendees will be better able to:
- Recognize the benefits and risks of the various anticoagulant and antiplatelet agents used in conjunction with PCI
- Understand the factors which influence drug selection and duration of dual antiplatelet therapy
- Address various strategies when combined anticoagulation and antiplatelet are required, for example, PCI in patients with atrial fibrillation